JNJ ▲ +1.4% - Johnson & Johnson
$JNJ - Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
07-NOV-2026 10:03 AM ET
Share this post
More filings for $JNJ
JNJ ▲ +1.4% - Johnson & JohnsonNov 7, 2026JNJ ▼ -1.8% - Johnson & JohnsonNov 6, 2026JNJ ▲ +0.1% - Johnson & JohnsonOct 27, 2026JNJ ▲ +1.0% - Johnson & JohnsonOct 22, 2026JNJ ▼ -0.7% - Johnson & JohnsonOct 21, 2026JNJ ▲ +0.8% - Johnson & JohnsonOct 20, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment